β-amyloid disrupting drugs: Potential in the treatment of Alzheimer's disease

CNS Drugs

Volumn 12, Issue 5, 1999, Pages 347-356

  Soto, C ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTHRACYCLINE 4' IODO 4' DEOXYDORUBICIN; ANTHRACYCLINE DERIVATIVE; CLUSTERIN; CONGO RED; HEXADECYL N METHYLPIPERIDINIUM; LAMININ; MELATONIN; NATURAL PRODUCT; NICOTINE; PPI 433; PPI 457; PREALBUMIN; PTI 00703; RIFAMPICIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; DEGENERATIVE DISEASE; HUMAN; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW;

EID: 0032741613     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912050-00002     Document Type: Review

References (68)

1. 1. DS Geldmacher PJ Whitehouse 1997 Differential diagnosis of Alzheimer’s disease Neurology 48 S2 S9 9153154 10.1212/WNL.48.5_Suppl_6.2S 1:STN:280:DyaK2s3pslKrtA%3D%3D Geldmacher DS, Whitehouse PJ. Differential diagnosis of Alzheimer’s disease. Neurology 1997; 48: S2–S9
2. 2. R Katzman T Saitoh 1991 Advances in Alzheimer’s disease FASEB J 5 278 86 2001787 1:CAS:528:DyaK3MXhs1WksLo%3D Katzman R, Saitoh T. Advances in Alzheimer’s disease. FASEB J 1991; 5: 278–86
3. 3. E Giocobini 1998 Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications Neurochem Int 32 413 9 10.1016/S0197-0186(97)00124-1 Giocobini E. Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochem Int 1998; 32: 413–9
4. 4. D Knopman JC Morris 1998 An update on primary drug therapies for Alzheimer’s disease Arch Neurol 54 1406 9 10.1001/archneur.1997.00550230073020 Knopman D, Morris JC. An update on primary drug therapies for Alzheimer’s disease. Arch Neurol 1998; 54: 1406–9
5. 5. DJ Selkoe 1991 The molecular pathology of Alzheimer’s disease Neuron 6 487 98 1673054 10.1016/0896-6273(91)90052-2 1:CAS:528:DyaK3MXltlartrk%3D Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron 1991; 6: 487–98
6. 6. I Grundke-Iqbal K Iqbal M Quinlan 1986 Microtubule-associated protein tau. A component of Alzheimer paired helical filaments J Biol Chem 261 6084 9 3084478 1:CAS:528:DyaL28XitVCqsb0%3D Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084–9
7. 7. J Hardy D Allsop 1991 Amyloid deposition as the central event in the aetiology of Alzheimer’s disease Trends Pharmacol Sci 12 383 8 1763432 10.1016/0165-6147(91)90609-V 1:CAS:528:DyaK3MXmslKktr8%3D Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12: 383–8
8. 8. DJ Selkoe 1997 Neuroscience — Alzheimer’s disease: genotypes, phenotype, and treatments Science 275 630 1 9019820 10.1126/science.275.5300.630 1:CAS:528:DyaK2sXptVOmug%3D%3D Selkoe DJ. Neuroscience — Alzheimer’s disease: genotypes, phenotype, and treatments. Science 1997; 275: 630–1
9. 9. KE Wisniewski GA Jervis RC Moretz 1979 Alzheimer’s neurofibrillary tangles in diseases other than senile or presenile dementia Ann Neurol 5 228 94 10.1002/ana.410050311 Wisniewski KE, Jervis GA, Moretz RC, et al. Alzheimer’s neurofibrillary tangles in diseases other than senile or presenile dementia. Ann Neurol 1979; 5: 228–94
10. 10. GG Glenner 1980 Amyloid deposits and amyloidosis. The β-fibrilloses N Engl J Med 302 1283 92 6154243 10.1056/NEJM198006053022305 1:CAS:528:DyaL3cXkt1ektbc%3D Glenner GG. Amyloid deposits and amyloidosis. The β-fibrilloses. N Engl J Med 1980; 302: 1283–92
11. 11. JD Sipe 1992 Amyloidosis Ann Rev Biochem 61 947 75 1497327 10.1146/annurev.bi.61.070192.004503 1:CAS:528:DyaK3sXkslCg Sipe JD. Amyloidosis. Ann Rev Biochem 1992; 61: 947–75
12. 12. JE Maggio PW Mantyh 1996 Brain amyloid — a physicochemical perspective Brain Pathol 6 147 62 8737930 10.1111/j.1750-3639.1996.tb00797.x 1:CAS:528:DyaK28XivFykur0%3D Maggio JE, Mantyh PW. Brain amyloid — a physicochemical perspective. Brain Pathol 1996; 6: 147–62
13. 13. GG Glenner CW Wong 1984 Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem Biophys Res Commun 120 885 90 6375662 10.1016/S0006-291X(84)80190-4 1:CAS:528:DyaL2cXitVOntLw%3D Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885–90
14. 14. SS Sisodia DL Price 1995 Role of the β-amyloid protein in Alzheimer’s disease FASEB J 9 366 70 7896005 1:CAS:528:DyaK2MXks12ntrY%3D Sisodia SS, Price DL. Role of the β-amyloid protein in Alzheimer’s disease. FASEB J 1995; 9: 366–70
15. 15. E Gowing AE Roher AS Woods 1994 Chemical characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease J Biol Chem 269 10987 90 8157623 1:CAS:528:DyaK2cXivFGrt7w%3D Gowing E, Roher AE, Woods AS, et al. Chemical characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 1994; 269: 10987–90
16. 16. M Lalowski A Golabek CA Lemere 1996 The ‘nonamyloidogenic’ p3 fragment (amyloid β17-42) is a major constituent of Down’s syndrome cerebellar preamyloid J Biol Chem 271 33623 31 8969231 10.1074/jbc.271.52.33623 1:CAS:528:DyaK2sXit1Kluw%3D%3D Lalowski M, Golabek A, Lemere CA, et al. The ‘nonamyloidogenic’ p3 fragment (amyloid β17-42) is a major constituent of Down’s syndrome cerebellar preamyloid. J Biol Chem 1996; 271: 33623–31
17. 17. G Giaccone F Tagliavini G Linoli 1989 Down’s syndrome: extracellular preamyloid deposits precede neuritic degeneration and senile plaques Neurosci Lett 97 232 8 2521927 10.1016/0304-3940(89)90169-9 1:STN:280:DyaL1M7ksVahtg%3D%3D Giaccone G, Tagliavini F, Linoli G, et al. Down’s syndrome: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 1989; 97: 232–8
18. 18. C Haass MG Schlossmacher AY Hung 1992 Amyloid beta-peptide is produced by cultured cells during normal metabolism Nature 359 322 5 1383826 10.1038/359322a0 1:CAS:528:DyaK38XmtV2msro%3D Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359: 322–5
19. 19. P Seubert C Vigo-Pelfrey F Esch 1992 Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids Nature 359 325 7 1406936 10.1038/359325a0 1:CAS:528:DyaK38XmtFSisrc%3D Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature 1992; 359: 325–7
20. 20. M Shoji TE Golde J Ghiso 1992 Production of the Alzheimer amyloid beta protein by normal proteolytic processing Science 258 126 9 1439760 10.1126/science.1439760 1:CAS:528:DyaK38XmtlSrs70%3D Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258: 126–9
21. 21. DB Teplow 1998 Structural and kinetic features of amyloid beta-protein fibrillogenesis Amyloid 5 121 42 9686307 10.3109/13506129808995290 1:CAS:528:DyaK1cXkvVensLw%3D Teplow DB. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 1998; 5: 121–42
22. 22. EM Castaño J Ghiso F Prelli 1986 In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease beta-protein Biochem Biophys Res Commun 141 782 9 3541938 10.1016/S0006-291X(86)80241-8 Castaño EM, Ghiso J, Prelli F, et al. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease beta-protein. Biochem Biophys Res Commun 1986; 141: 782–9
23. 23. C Soto MC Branes J Alvarez 1994 Structural determinants of the Alzheimer’s amyloid beta-peptide J Neurochem 63 1191 8 7931272 10.1046/j.1471-4159.1994.63041191.x 1:CAS:528:DyaK2cXmtVWqtb0%3D Soto C, Branes MC, Alvarez J, et al. Structural determinants of the Alzheimer’s amyloid beta-peptide. J Neurochem 1994; 63: 1191–8
24. 24. C Soto EM Castaño RA Kumar 1995 Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure Neurosci Lett 200 105 8 8614555 10.1016/0304-3940(95)12089-M 1:CAS:528:DyaK2MXpsV2rsbs%3D Soto C, Castaño EM, Kumar RA, et al. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure. Neurosci Lett 1995; 200: 105–8
25. 25. LK Simmons PC May KJ Tomaselli 1994 Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro Mol Pharmacol 45 373 9 8145724 1:CAS:528:DyaK2cXitlOrt7Y%3D Simmons LK, May PC, Tomaselli KJ, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994; 45: 373–9
26. 26. JT Jarrett EP Berger PT Lansbury Jr 1993 The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease Biochem 32 4693 7 10.1021/bi00069a001 1:CAS:528:DyaK3sXksVKktL0%3D Jarrett JT, Berger EP, Lansbury Jr PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochem 1993; 32: 4693–7
27. 27. SG Younkin 1995 Evidence that Aβ 42 is the real culprit in Alzheimer’s disease Ann Neurol 37 287 8 7695227 10.1002/ana.410370303 1:CAS:528:DyaK2MXltFeqsL8%3D Younkin SG. Evidence that Aβ 42 is the real culprit in Alzheimer’s disease. Ann Neurol 1995; 37: 287–8
28. 28. C Hilbich B Kisters-Woike J Reed 1992 Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer’s disease βA4 peptides J Mol Biol 228 460 73 1453457 10.1016/0022-2836(92)90835-8 1:CAS:528:DyaK3sXkvFarur8%3D Hilbich C, Kisters-Woike B, Reed J, et al. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer’s disease βA4 peptides. J Mol Biol 1992; 228: 460–73
29. 29. JD Wood R Wetzel JD Martin 1995 Prolines and amyloidogenicity in fragments of the Alzheimer’s peptide β/A4 Biochem 34 724 30 10.1021/bi00003a003 1:CAS:528:DyaK2MXjtVyrtbw%3D Wood JD, Wetzel R, Martin JD, et al. Prolines and amyloidogenicity in fragments of the Alzheimer’s peptide β/A4. Biochem 1995; 34: 724–30
30. 30. C Soto EM Castaño B Frangione 1995 The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation J Biol Chem 270 3063 7 7852387 10.1074/jbc.270.7.3063 1:CAS:528:DyaK2MXjslahtLk%3D Soto C, Castaño EM, Frangione B, et al. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 1995; 270: 3063–7
31. 31. LO Tjernberg J Naslund F Lindqvist 1996 Arrest of β-amyloid fibril formation by a pentapeptide ligand J Biol Chem 271 8545 8 8621479 10.1074/jbc.271.15.8545 1:CAS:528:DyaK28Xitlegu7k%3D Tjernberg LO, Naslund J, Lindqvist F, et al. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545–8
32. 32. OM El-Agnaf DJ Guthrie DM Walsh 1998 The influence of the central region containing residues 19–25 on the aggregation properties and secondary structure of Alzheimer’s beta-amyloid peptide Eur J Biochem 256 560 9 9780232 10.1046/j.1432-1327.1998.2560560.x 1:CAS:528:DyaK1cXmtlCgur4%3D El-Agnaf OM, Guthrie DJ, Walsh DM, et al. The influence of the central region containing residues 19–25 on the aggregation properties and secondary structure of Alzheimer’s beta-amyloid peptide. Eur J Biochem 1998; 256: 560–9
33. 33. M Mullan F Crawford 1994 The molecular genetics of Alzheimer’s disease Mol Neurobiol 9 15 22 7888092 10.1007/BF02816100 1:CAS:528:DyaK2MXjtV2gt7k%3D Mullan M, Crawford F. The molecular genetics of Alzheimer’s disease. Mol Neurobiol 1994; 9: 15–22
34. 34. AI Bush WH Pettingell G Multhaup 1994 Rapid induction of Alzheimer Aβ amyloid formation by zinc Science 265 1464 7 8073293 10.1126/science.8073293 1:CAS:528:DyaK2cXmsFaqs7k%3D Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 1994; 265: 1464–7
35. 35. AD Snow TN Wight 1989 Proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidosis Neurobiol Aging 10 481 97 2682326 10.1016/0197-4580(89)90108-5 1:CAS:528:DyaL1MXmt12rt74%3D Snow AD, Wight TN. Proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidosis. Neurobiol Aging 1989; 10: 481–97
36. 36. AA Golabek C Soto T Vogel 1996 The interaction between Alzheimer β-peptide and apolipoprotein E is dependent on β-peptide conformation J Biol Chem 271 10602 6 8631862 10.1074/jbc.271.52.33623 1:CAS:528:DyaK28XivVaqtrk%3D Golabek AA, Soto C, Vogel T, et al. The interaction between Alzheimer β-peptide and apolipoprotein E is dependent on β-peptide conformation. J Biol Chem 1996; 271: 10602–6
37. 37. CJ Barrow A Yasuda PT Kenny 1992 Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer’s disease. Analysis of circular dichroism spectra J Mol Biol 225 1075 93 1613791 10.1016/0022-2836(92)90106-T 1:CAS:528:DyaK38XltV2gs7g%3D Barrow CJ, Yasuda A, Kenny PT, et al. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer’s disease. Analysis of circular dichroism spectra. J Mol Biol 1992; 225: 1075–93
38. 38. MG Zagorski CJ Barrow 1992 NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix—beta-sheet conversion for a homologous, 28-residue, N-terminal fragment Biochemistry 31 24 5621 31 1610809 10.1021/bi00139a028 1:CAS:528:DyaK38XktVGns7k%3D Zagorski MG, Barrow CJ. NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix—beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry 1992; 31(24): 5621–31
39. 39. C Soto EM Castaño 1996 The conformation of Alzheimer’s β peptide determines the rate of amyloid formation and its resistance to proteolysis Biochem J 314 701 7 8670088 1:CAS:528:DyaK28XhslCktr4%3D Soto C, Castaño EM. The conformation of Alzheimer’s β peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 1996; 314: 701–7
40. 40. C Hilbich B Kisters-Woike J Reed 1991 Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer’s disease J Mol Biol 218 149 63 2002499 10.1016/0022-2836(91)90881-6 1:CAS:528:DyaK3MXhs1Wqtr0%3D Hilbich C, Kisters-Woike B, Reed J, et al. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer’s disease. J Mol Biol 1991; 218: 149–63
41. 41. JP Lee ER Stimson J Ghilardi 1995 H-1 NMR of A-beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence Biochemistry 34 15 5191 200 7711039 10.1021/bi00015a033 1:CAS:528:DyaK2MXkvFGitrw%3D Lee JP, Stimson ER, Ghilardi J, et al. H-1 NMR of A-beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry 1995; 34(15): 5191–200
42. 42. A Lorenzo BA Yankner 1994 Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red Proc Natl Acad Sci U S A 91 12243 7 7991613 10.1073/pnas.91.25.12243 1:CAS:528:DyaK2MXisF2jsL4%3D Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 1994; 91: 12243–7
43. 43. G Merlini E Ascari N Amboldi 1995 Interaction of the anthra-cycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of fibrillogenesis Proc Natl Acad Sci U S A 92 2959 64 7708755 10.1073/pnas.92.7.2959 1:CAS:528:DyaK2MXksl2rtbs%3D Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthra-cycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of fibrillogenesis. Proc Natl Acad Sci U S A 1995; 92: 2959–64
44. 44. T Tomiyama A Shoji K Kataoka 1996 Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin — its possible function as a hydroxyl radical scavenger J Biol Chem 271 6839 44 8636108 10.1074/jbc.271.12.6839 1:CAS:528:DyaK28XhvVyisb0%3D Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin — its possible function as a hydroxyl radical scavenger. J Biol Chem 1996; 271: 6839–44
45. 45. SJ Wood L MacKenzie B Maleeff 1996 Selective inhibition of Aβ fibril formation J Biol Chem 271 4086 92 8626745 10.1074/jbc.271.48.30392 1:CAS:528:DyaK28XhtlSmsL0%3D Wood SJ, MacKenzie L, Maleeff B, et al. Selective inhibition of Aβ fibril formation. J Biol Chem 1996; 271: 4086–92
46. 46. R Kisilevsky LJ Lemieux PE Fraser 1995 Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease Nat Med 1 2 143 8 7585011 10.1038/nm0295-143 1:CAS:528:DyaK2MXksVeru74%3D Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nat Med 1995; 1(2): 143–8
47. 47. AR Salomon KJ Marcinowski R Friedland 1996 Nicotine inhibits amyloid formation by the β-peptide Biochemistry 35 13568 78 8885836 10.1021/bi9617264 1:CAS:528:DyaK28XlvFequ7c%3D Salomon AR, Marcinowski KJ, Friedland R, et al. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 1996; 35: 13568–78
48. 48. M Pappolla P Bozner C Soto 1998 Inhibition of Alzheimer β-fibrillogenesis by melatonin J Biol Chem 273 7185 8 9516407 10.1074/jbc.273.13.7185 1:CAS:528:DyaK1cXit1emt7Y%3D Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185–8
49. 49. D McCurley GM Castillo AD Snow 1998 Therapeutic implications of PTI-00703: a natural plant extract that is a potent dissolver of Alzheimer’s disease amyloid [abstract] Neurobiol Aging 19 S256 McCurley D, Castillo GM, Snow AD. Therapeutic implications of PTI-00703: a natural plant extract that is a potent dissolver of Alzheimer’s disease amyloid [abstract]. Neurobiol Aging 1998; 19: S256
50. 50. AL Schwarzman L Gregori MP Vitek 1994 Transthyretin sequesters amyloid beta protein and prevents amyloid formation Proc Natl Acad Sci U S A 91 8368 72 8078889 10.1073/pnas.91.18.8368 1:CAS:528:DyaK2cXlslKktLk%3D Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 1994; 91: 8368–72
51. 51. PE Fraser JT Nguyen DR McLachlan 1993 Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro J Neurochem 61 298 305 8515277 10.1111/j.1471-4159.1993.tb03568.x 1:CAS:528:DyaK3sXlsFOmsrg%3D Fraser PE, Nguyen JT, McLachlan DR, et al. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61: 298–305
52. 52. FC Bronfman J Garrido A Alvarez 1996 Laminin inhibits amyloid-β-peptide fibrillation Neurosci Lett 218 201 3 8945763 10.1016/S0304-3940(96)13147-5 1:CAS:528:DyaK28Xnt1Oiu7g%3D Bronfman FC, Garrido J, Alvarez A, et al. Laminin inhibits amyloid-β-peptide fibrillation. Neurosci Lett 1996; 218: 201–3
53. 53. E Matsubara C Soto S Governale 1996 Apolipoprotein J and Alzheimer’s amyloid-β solubility Biochem J 316 371 9 Matsubara E, Soto C, Governale S, et al. Apolipoprotein J and Alzheimer’s amyloid-β solubility. Biochem J 1996; 316: 371–9
54. 54. S Janciauskiene F P De E Carlemalm 1995 Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component J Biol Chem 270 26041 4 7592799 10.1074/jbc.270.44.26041 1:CAS:528:DyaK2MXpt1ejtLg%3D Janciauskiene S, De Frutos PG, Carlemalm E, et al. Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component. J Biol Chem 1995; 270: 26041–4
55. 55. C Soto MS Kindy M Baumann 1996 Inhibition of Alzheimer’s amyloidosis by peptides that prevent β-sheet conformation Biochem Biophys Res Commun 226 672 80 8831674 10.1006/bbrc.1996.1413 1:CAS:528:DyaK28XlvFagsbg%3D Soto C, Kindy MS, Baumann M, et al. Inhibition of Alzheimer’s amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672–80
56. 56. J Ghanta CL Shen LL Kiessling 1996 A strategy for designing inhibitors of β-amyloid toxicity J Biol Chem 271 29525 8 8939877 10.1074/jbc.271.47.29525 1:CAS:528:DyaK28XntFKmsrw%3D Ghanta J, Shen CL, Kiessling LL, et al. A strategy for designing inhibitors of β-amyloid toxicity. J Biol Chem 1996; 271: 29525–8
57. 57. BJ Blanchard G Konopa M Russell 1997 Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer’s disease Brain Res 776 40 50 9439794 10.1016/S0006-8993(97)01003-2 1:CAS:528:DyaK2sXnvFGms70%3D Blanchard BJ, Konopa G, Russell M, et al. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer’s disease. Brain Res 1997; 776: 40–50
58. 58. C Soto EM Sigurdsson L Morelli 1998 β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy Nat Med 4 822 6 9662374 10.1038/nm0798-822 1:CAS:528:DyaK1cXktlKnsrg%3D Soto C, Sigurdsson EM, Morelli L, et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. Nat Med 1998; 4: 822–6
59. 59. MA Findeis GM Musso CC Arico-Muendel 1999 Modified-peptide inhibitors of amyloid β-peptide polymerization Biochemistry 38 6791 800 10346900 10.1021/bi982824n 1:CAS:528:DyaK1MXislyitrw%3D Findeis MA, Musso GM, Arico-Muendel CC, et al. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 1999; 38: 6791–800
60. 60. C Soto J Ghiso B Frangione 1997 Alzheimer’s amyloid-β aggregation is modulated by the interaction of multiple factors Alzheimer’s Res 3 215 22 Soto C, Ghiso J, Frangione B. Alzheimer’s amyloid-β aggregation is modulated by the interaction of multiple factors. Alzheimer’s Res 1997; 3: 215–22
61. 61. D Schenk R Barbour W Dunn 1999 Immunization with amyloid-β attenuates Alzheimer’s disease like pathology in the PDAPP mouse Nature 400 173 7 10408445 10.1038/22124 1:CAS:528:DyaK1MXks1Khsbc%3D Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer’s disease like pathology in the PDAPP mouse. Nature 1999; 400: 173–7
62. 62. S-C Li NK Goto KA Williams 1996 Alpha-helical but not beta-sheet propensity of proline is determined by peptide environment Proc Natl Acad Sci U S A 93 6676 81 8692877 10.1073/pnas.93.13.6676 1:CAS:528:DyaK28XjvFeisLg%3D Li S-C, Goto NK, Williams KA, et al. Alpha-helical but not beta-sheet propensity of proline is determined by peptide environment. Proc Natl Acad Sci U S A 1996; 93: 6676–81
63. 63. EM Sigurdsson L Morelli AR Kumar 1998 β-sheet breaker peptides prevent Alzheimer’s amyloid formation in vivo Alzheimer’s Reports 1 S35 S36 Sigurdsson EM, Morelli L, Kumar AR, et al. β-sheet breaker peptides prevent Alzheimer’s amyloid formation in vivo. Alzheimer’s Reports 1998; 1: S35–S36
64. 64. PJ Thomas B-H Qu PL Pedersen 1995 Defective protein folding as a basis of human disease Trends Biochem Sci 20 456 9 8578588 10.1016/S0968-0004(00)89100-8 1:CAS:528:DyaK2MXpsF2mur0%3D Thomas PJ, Qu B-H, Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 1995; 20: 456–9
65. 65. RW Carrell DA Lomas 1997 Conformational disease Lancet 350 134 8 9228977 10.1016/S0140-6736(97)02073-4 1:CAS:528:DyaK2sXkvFeis7s%3D Carrell RW, Lomas DA. Conformational disease. Lancet 1997; 350: 134–8
66. 66. C Soto 1999 Alzheimer’s and prion diseases as disorders of protein conformation: implications for the design of novel therapeutic approaches J Mol Med 77 5 412 8 10426190 10.1007/s001090050371 1:CAS:528:DyaK1MXkvV2rt7w%3D Soto C. Alzheimer’s and prion diseases as disorders of protein conformation: implications for the design of novel therapeutic approaches. J Mol Med 1999; 77(5): 412–8
67. 67. JW Kelly 1996 Alternative conformations of amyloidogenic proteins govern their behavior Curr Opin Struct Biol 6 11 7 8696966 10.1016/S0959-440X(96)80089-3 1:CAS:528:DyaK28Xhtlamtrk%3D Kelly JW. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996; 6: 11–7
68. 68. Soto C, Kascsak RJ, Wisniewski T, et al. The Prion protein conformational changes associated with the pathogenesis of Spongiform Encephalopathies can be inhibited and reversed by synthetic peptides designed as β-sheet breakers. 27th Annual Meeting Society for Neuroscience: 1997 Oct 25–30: New Orleans (LA)